{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:22:51Z","timestamp":1787502171123,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T02:32:09Z","timestamp":1672972329000},"page":"1003-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series"],"prefix":"10.1016","volume":"41","author":[{"given":"Narges","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Mazdak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7798","key":"10.1016\/j.vaccine.2023.01.003_b0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.01.003_b0010","article-title":"Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study","author":"Mao","year":"2020","journal-title":"MedRxiv"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.003_b0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.vaccine.2023.01.003_b0020","article-title":"Multiple sclerosis following SARS-CoV-2 infection: a case report and literature review","volume":"13","author":"Sarwar","year":"2021","journal-title":"Cureus"},{"issue":"10269","key":"10.1016\/j.vaccine.2023.01.003_b0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.003_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ane.13417","article-title":"The potential neurological effect of the COVID-19 vaccines: a review","volume":"144","author":"Lu","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.003_b0035","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1016\/j.radcr.2021.09.033","article-title":"Post COVID-19 vaccination neuromyelitis optica spectrum disorder: case report & MRI findings","volume":"16","author":"Badrawi","year":"2021","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.vaccine.2023.01.003_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577755","article-title":"Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"361","author":"Fujimori","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.003_b0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00415-021-10648-w","article-title":"First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"269","author":"Havla","year":"2022","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.003_b0050","first-page":"772","article-title":"A rare presentation of undiagnosed multiple sclerosis after the COVID-19 vaccine","volume":"11","author":"Tagliaferri","year":"2021","journal-title":"J Commun Hosp Int Med Perspect"},{"key":"10.1016\/j.vaccine.2023.01.003_b0055","series-title":"Seminars in immunopathology","article-title":"The pathological spectrum of CNS inflammatory demyelinating diseases","author":"Hu","year":"2009"},{"issue":"77","key":"10.1016\/j.vaccine.2023.01.003_b0060","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1016\/j.med.2015.04.001","article-title":"Enfermedades desmielinizantes del sistema nervioso central","volume":"11","author":"Fern\u00e1ndez","year":"2015","journal-title":"Medicine-Programa de Formaci\u00f3n M\u00e9dica Continuada Acreditado"},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.003_b0065","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tig.2017.09.004","article-title":"The genetics of multiple sclerosis: from 0 to 200 in 50 years","volume":"33","author":"Baranzini","year":"2017","journal-title":"Trends Genet"},{"key":"10.1016\/j.vaccine.2023.01.003_b0070","doi-asserted-by":"crossref","unstructured":"Hinson SR et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci 2012;109(4):1245\u201350.","DOI":"10.1073\/pnas.1109980108"},{"issue":"9451","key":"10.1016\/j.vaccine.2023.01.003_b0075","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.003_b0080","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2023.01.003_b0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jns.2010.10.013","article-title":"A serological analysis of viral and bacterial infections associated with neuromyelitis optica","volume":"300","author":"Koga","year":"2011","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.003_b0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(05)70054-5","article-title":"Infectious causes of multiple sclerosis","volume":"4","author":"Holm\u00f8y","year":"2005","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.003_b0095","article-title":"Author correction: multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"26","key":"10.1016\/j.vaccine.2023.01.003_b0100","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1056\/NEJMc2009191","article-title":"Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2","volume":"382","author":"Toscano","year":"2020","journal-title":"N Engl J Med"},{"issue":"10.1016","key":"10.1016\/j.vaccine.2023.01.003_b0105","article-title":"Sars-Cov-2: underestimated damage to nervous system","volume":"101642","author":"Zhou","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.003_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102474","article-title":"Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report","volume":"46","author":"de Ruijter","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"S1","key":"10.1016\/j.vaccine.2023.01.003_b0115","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/ana.410360709","article-title":"Influence of infection on exacerbations of multiple sclerosis","volume":"36","author":"Panitch","year":"1994","journal-title":"Ann Neurol: Off J Am Neurol Assoc Child Neurol Soc"},{"key":"10.1016\/j.vaccine.2023.01.003_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103394","article-title":"Vaccination in neuromyelitis optica spectrum disorders: friend or enemy?","volume":"58","author":"Cai","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.003_b0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.003_b0130","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00415-021-10780-7","article-title":"COVID-19 mRNA vaccination leading to CNS inflammation: a case series","volume":"269","author":"Khayat-Khoei","year":"2022","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.vaccine.2023.01.003_b0135","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1212\/01.wnl.0000335762.42177.07","article-title":"Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood","volume":"72","author":"Mikaeloff","year":"2009","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.vaccine.2023.01.003_b0140","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrrheum.2009.196","article-title":"Vaccines and autoimmunity","volume":"5","author":"Agmon-Levin","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.vaccine.2023.01.003_b0145","doi-asserted-by":"crossref","unstructured":"Agmon-Levin N, Hughes G, Shoenfeld Y. The spectrum of ASIA:\u2018Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants\u2019. London, England: Sage Publications; 2012. p. 118\u201320.","DOI":"10.1177\/0961203311429316"},{"key":"10.1016\/j.vaccine.2023.01.003_b0150","doi-asserted-by":"crossref","unstructured":"Vojdani A, Kharrazian D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol (Orlando, Fla.) 2020;217:108480.","DOI":"10.1016\/j.clim.2020.108480"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.003_b0155","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/S2666-5247(21)00033-1","article-title":"Molecular mimicry in the post-COVID-19 signs and symptoms of neurovegetative disorders?","volume":"2","author":"Gammazza","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2023.01.003_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin Immunol (Orlando, Fla.)"},{"issue":"13","key":"10.1016\/j.vaccine.2023.01.003_b0165","first-page":"p. 1217e25","article-title":"Adjuvants and autoimmunity","volume":"18","author":"Eitan","year":"2009","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.003_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-022-07069-z","article-title":"RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine","volume":"22","author":"Ferenci","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.003_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577765","article-title":"A systematic review of cases of CNS demyelination following COVID-19 vaccination","volume":"362","author":"Ismail","year":"2022","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.vaccine.2023.01.003_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103321","article-title":"New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19","volume":"57","author":"Fragoso","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.003_b0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.003_b0190","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/brainsci12030407","article-title":"COVID-19 vaccination and neurological manifestations: a review of case reports and case series","volume":"12","author":"Sriwastava","year":"2022","journal-title":"Brain Sci"},{"key":"10.1016\/j.vaccine.2023.01.003_b0195","doi-asserted-by":"crossref","unstructured":"Korn T et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci 2008;105(47):18460\u20135.","DOI":"10.1073\/pnas.0809850105"},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.003_b0200","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1007\/s10072-021-05427-4","article-title":"Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19","volume":"42","author":"Chen","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.vaccine.2023.01.003_b0205","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fneur.2020.00851","article-title":"Comorbidity in multiple sclerosis","volume":"11","author":"Magyari","year":"2020","journal-title":"Front Neurol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:17Z","timestamp":1759404197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2300004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X2300004X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}